Silica Corpora is a cutting-edge AI-powered platform company specializing in the design and optimization of therapeutic antibodies targeting priority diseases. Founded in 2022 and headquartered in Berlin, Germany, the company emerged from the shared vision of its founders Tim Ermak and Jaime Rosselló to transform drug discovery with generative technologies.

Silica Corpora's proprietary AI-based platform leverages machine learning and data analytics to work exclusively with amino acid sequences, enabling the design of novel antibodies with precision, efficiency, and control.

The company's modular system includes several innovative modules such as Generator, Discriminator, Optimizer, and Ep-Mapper, which collectively generate and optimize antibody candidates represented as amino acid sequences.

Silica Corpora's platform offers a holistic approach to drug discovery, taking into account multiple parameters needed for successful candidate creation and focusing on the system as a whole rather than single properties.

The platform is adaptive, efficient, and designed to work with fine-tuned project-specific data, enabling applications alongside established workflows without the need for new equipment or additional personnel.

Silica Corpora has established strategic partnerships with notable organizations including Berkeley Skydeck, SIB (Swiss Institute of Bioinformatics), Charité, Google Cloud, Exist, 5HT, Fraunhofer, and others to drive innovation and expand their impact in the biopharmaceutical field.

The leadership team includes founders Tim Ermak and Jaime Rosselló and Chief Scientific Officer Anna-Catharina Krebs, who joined in 2023 bringing extensive lab science expertise to accelerate platform development.

The company's mission is to develop advanced De Novo solutions to enhance the quality and cost-effectiveness of antibody therapeutics for diseases with high unmet medical needs.